CERTIFICATION OF FACSIMILE TRANSMISSION I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below. Type or print name of person signing certification Signature Date

PATENT IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U. S. Patent No. 7414132

Issued: August 19, 2008

First Applicant DE LA TORRE, Marta Garcia

Serial No. 10/581178

Application Date December 15, 2004

OPIOID RECEPTOR ANTAGONISTS Entitled

Docket No. X-16440

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. 1.322

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The patentees of the above-identified patent respectfully request that you issue a Certificate of Correction to correct errors which occurred during the printing of the patent. The printing errors are not errors of the patentee as evidenced by, for example, the application transmittal letter and the filing receipt.

A copy of Form PTO 1050 on which the errors are specified accompanies this document.

Respectfully submitted,

/John C. Demeter/ John C. Demeter Attorney for Patentees Registration No. 30,167 Phone: 317-276-3785

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288

October 27, 2010

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. 7414132

Page 1 of 1

APPLICATION NO.: 10/581178

ISSUE DATE : August 19, 2008

INVENTOR(S) : DE LA TORRE, Marta Garcia, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title page:

Insert -- (60) Related U.S. Application Data
Provisional application no. 60/539,748, filed January 28, 2004.--

On the first page of the specification, insert the following cross-reference after the title:

--This application is the national phase application, under 35 USC 371, for PCT/US2004/039766, filed December 15, 2004, which claims the benefit, under 35 USC 119(e), of EP application 03380303.2, filed December 22, 2003, and US provisional application 60/539,748, filed January 28, 2004.--

MAILING ADDRESS OF SENDER (Please do not use customer number below): Eli Lilly and Company

P.O. Box 6288

Indianapolis, IN 46206-6288

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.